银屑病表观遗传调控的研究进展

doi:10.35541/cjd.20200318

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (9): 825-829.doi: 10.35541/cjd.20200318

银屑病表观遗传调控的研究进展

刘晋沈征宇

上海交通大学医学院附属第九人民医院皮肤科，上海 200011

收稿日期:2020-04-01 修回日期:2020-10-13 发布日期:2022-09-02
通讯作者: 沈征宇 E-mail:neuronszy@sina.com
基金资助:
上海交通大学医学院附属第九人民医院“交叉”研究基金（JYJC201901）

Epigenetic regulation in psoriasis

Liu Jin, Shen Zhengyu

Department of Dermatology, Shanghai Ninth People′s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai 200011, China

Received:2020-04-01 Revised:2020-10-13 Published:2022-09-02
Contact: Shen Zhengyu E-mail:neuronszy@sina.com
Supported by:
Cross-disciplinary Research Fund of Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine（JYJC201901）

摘要/Abstract

摘要： 【摘要】研究显示，银屑病患者体内存在大量异常的表观遗传改变，包括DNA甲基化、组蛋白修饰、非编码RNA调节等，提示表观遗传机制可能参与了银屑病的发病。该文综述银屑病表观遗传调控的研究进展。

关键词: 银屑病, 表观遗传学, 发病机制

Abstract: 【Abstract】 Studies have shown a large number of aberrant epigenetic changes in patients with psoriasis, including DNA methylation, histone modification, non-coding RNA regulation, etc., suggesting that epigenetic mechanisms may be involved in the occurrence of psoriasis. This review focuses on the recent progress in epigenetic regulation in psoriasis.

Key words: Psoriasis, Epigenetics, Pathogenesis

刘晋沈征宇. 银屑病表观遗传调控的研究进展[J]. 中华皮肤科杂志, 2022,55(9):825-829. doi:10.35541/cjd.20200318

Liu Jin, Shen Zhengyu. Epigenetic regulation in psoriasis[J]. Chinese Journal of Dermatology, 2022, 55(9): 825-829.doi:10.35541/cjd.20200318

参考文献 52

［1］	Pollock RA, Abji F, Gladman DD. Epigenetics of psoriatic disease: a systematic review and critical appraisal［J］. J Autoimmun, 2017,78:29⁃38. doi: 10.1016/j.jaut.2016.12.002.
［2］	Frischknecht L, Vecellio M, Selmi C. The role of epigenetics and immunological imbalance in the etiopathogenesis of psoriasis and psoriatic arthritis［J］. Ther Adv Musculoskelet Dis, 2019,11:1759720X19886505. doi: 10.1177/1759720X19886505.
［3］	Rendon A, Schäkel K. Psoriasis pathogenesis and treatment［J］. Int J Mol Sci, 2019,20（6）:1475. doi: 10.3390/ijms20061475.
［4］	Barros SP, Hefni E, Nepomuceno R, et al. Targeting epigenetic mechanisms in periodontal diseases［J］. Periodontol 2000, 2018,78（1）:174⁃184. doi: 10.1111/prd.12231.
［5］	Mervis JS, McGee JS. DNA methylation and inflammatory skin diseases［J］. Arch Dermatol Res, 2020,312（7）:461⁃466. doi: 10. 1007/s00403⁃019⁃02005⁃9.
［6］	Chen M, Wang Y, Yao X, et al. Hypermethylation of HLA⁃C may be an epigenetic marker in psoriasis［J］. J Dermatol Sci, 2016,83（1）:10⁃16. doi: 10.1016/j.jdermsci.2016.04.003.
［7］	Yooyongsatit S, Ruchusatsawat K, Noppakun N, et al. Patterns and functional roles of LINE⁃1 and Alu methylation in the keratinocyte from patients with psoriasis vulgaris［J］. J Hum Genet, 2015,60（7）:349⁃355. doi: 10.1038/jhg.2015.33.
［8］	Suarez NA, Macia A, Muotri AR. LINE⁃1 retrotransposons in healthy and diseased human brain［J］. Dev Neurobiol, 2018,78（5）:434⁃455. doi: 10.1002/dneu.22567.
［9］	Zhou F, Wang W, Shen C, et al. Epigenome⁃wide association analysis identified nine skin DNA methylation loci for psoriasis［J］. J Invest Dermatol, 2016,136（4）:779⁃787. doi: 10.1016/j.jid.2015.12.029.
［10］	Verma D, Ekman AK, Bivik Eding C, et al. Genome⁃wide DNA methylation profiling identifies differential methylation in uninvolved psoriatic epidermis［J］. J Invest Dermatol, 2018,138（5）:1088⁃1093. doi: 10.1016/j.jid.2017.11.036.
［11］	Giudice V, Wu Z, Kajigaya S, et al. Circulating S100A8 and S100A9 protein levels in plasma of patients with acquired aplastic anemia and myelodysplastic syndromes［J］. Cytokine, 2019,113:462⁃465. doi: 10.1016/j.cyto.2018.06.025.
［12］	Roberson ED, Liu Y, Ryan C, et al. A subset of methylated CpG sites differentiate psoriatic from normal skin［J］. J Invest Dermatol, 2012,132（3 Pt 1）:583⁃592. doi: 10.1038/jid.2011.348.
［13］	Granata M, Skarmoutsou E, Gangemi P, et al. S100A7, Jab1, and p27kip1 expression in psoriasis and S100A7 CRISPR⁃activated human keratinocyte cell line［J］. J Cell Biochem, 2019,120（3）:3384⁃3392. doi: 10.1002/jcb.27609.
［14］	D′Amico F, Granata M, Skarmoutsou E, et al. Biological therapy downregulates the heterodimer S100A8/A9 （calprotectin） expression in psoriatic patients［J］. Inflamm Res, 2018,67（7）:609⁃616. doi: 10.1007/s00011⁃018⁃1147⁃6.
［15］	Maurelli M, Gisondi P, Danese E, et al. Psoriasin （S100A7） is increased in the serum of patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2020,182（6）:1502⁃1503. doi: 10. 1111/bjd.18807.
［16］	Voss A, Bode G, Sopalla C, et al. Expression of S100A8/A9 in HaCaT keratinocytes alters the rate of cell proliferation and differentiation［J］. FEBS Lett, 2011,585（2）:440⁃446. doi: 10. 1016/j.febslet.2010.12.037.
［17］	Pashirzad M, Shafiee M, Rahmani F, et al. Role of Wnt5a in the pathogenesis of inflammatory diseases［J］. J Cell Physiol, 2017,232（7）:1611⁃1616. doi: 10.1002/jcp.25687.
［18］	Bai J, Liu Z, Xu Z, et al. Epigenetic downregulation of SFRP4 contributes to epidermal hyperplasia in psoriasis［J］. J Immunol, 2015,194（9）:4185⁃4198. doi: 10.4049/jimmunol.1403196.
［19］	Whyte JM, Ellis JJ, Brown MA, et al. Best practices in DNA methylation: lessons from inflammatory bowel disease, psoriasis and ankylosing spondylitis［J］. Arthritis Res Ther, 2019,21（1）:133. doi: 10.1186/s13075⁃019⁃1922⁃y.
［20］	Brandt D, Sergon M, Abraham S, et al. TCR+CD3+CD4-CD8- effector T cells in psoriasis［J］. Clin Immunol, 2017,181:51⁃59. doi: 10.1016/j.clim.2017.06.002.
［21］	Zong W, Ge Y, Han Y, et al. Hypomethylation of HLA⁃DRB1 and its clinical significance in psoriasis［J］. Oncotarget, 2017,8（7）:12323⁃12332. doi: 10.18632/oncotarget.12468.
［22］	Chandra A, Senapati S, Roy S, et al. Epigenome⁃wide DNA methylation regulates cardinal pathological features of psoriasis［J］. Clin Epigenetics, 2018,10（1）:108. doi: 10.1186/s13148⁃018⁃0541⁃9.
［23］	Pollock RA, Zaman L, Chandran V, et al. Epigenome⁃wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis［J/OL］. PLoS One, 2019,14（2）:e0212043. doi: 10.1371/journal.pone.0212043.
［24］	Shen C, Wen L, Ko R, et al. DNA methylation age is not affected in psoriatic skin tissue［J］. Clin Epigenetics, 2018,10（1）:160. doi: 10.1186/s13148⁃018⁃0584⁃y.
［25］	Wu M, Li X, Zhang C, et al. DNA methylation profile of psoriatic skins from different body locations［J］. Epigenomics, 2019,11（14）:1613⁃1625. doi: 10.2217/epi⁃2018⁃0225.
［26］	Xu Y, Zhang S, Lin S, et al. WERAM: a database of writers, erasers and readers of histone acetylation and methylation in eukaryotes［J］. Nucleic Acids Res, 2017,45（D1）:D264⁃D270. doi: 10.1093/nar/gkw1011.
［27］	Zhang P, Su Y, Zhao M, et al. Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris［J］. Eur J Dermatol, 2011,21（4）:552⁃557. doi: 10.1684/ejd.2011.1383.
［28］	Ekman AK, Enerbäck C. Lack of preclinical support for the efficacy of histone deacetylase inhibitors in the treatment of psoriasis［J］. Br J Dermatol, 2016,174（2）:424⁃426. doi: 10. 1111/bjd.14021.
［29］	Sbidian E, Chaimani A, Garcia⁃Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta⁃analysis［J/CD］. Cochrane Database Syst Rev, 2017,12:CD011535. doi: 10.1002/14651858.CD011535.pub2.
［30］	Molinelli E, Campanati A, Brisigotti V, et al. Biologic therapy in psoriasis （Part II）: efficacy and safety of new treatment targeting IL23/IL⁃17 pathways［J］. Curr Pharm Biotechnol, 2017,18（12）:964⁃978. doi: 10.2174/1389201019666180103140643.
［31］	Li H, Yao Q, Mariscal AG, et al. Epigenetic control of IL⁃23 expression in keratinocytes is important for chronic skin inflammation［J］. Nat Commun, 2018,9（1）:1420. doi: 10.1038/s41467⁃018⁃03704⁃z.
［32］	Wu R, Zeng J, Yuan J, et al. MicroRNA⁃210 overexpression promotes psoriasis⁃like inflammation by inducing Th1 and Th17 cell differentiation［J］. J Clin Invest, 2018,128（6）:2551⁃2568. doi: 10.1172/JCI97426.
［33］	Ovejero⁃Benito MC, Reolid A, Sánchez⁃Jiménez P, et al. Histone modifications associated with biological drug response in moderate⁃to⁃severe psoriasis［J］. Exp Dermatol, 2018,27（12）:1361⁃1371. doi: 10.1111/exd.13790.
［34］	Lu TX, Rothenberg ME. MicroRNA［J］. J Allergy Clin Immunol, 2018,141（4）:1202⁃1207. doi: 10.1016/j.jaci.2017.08.034.
［35］	Srivastava A, Nikamo P, Lohcharoenkal W, et al. MicroRNA⁃146a suppresses IL⁃17⁃mediated skin inflammation and is genetically associated with psoriasis［J］. J Allergy Clin Immunol, 2017,139（2）:550⁃561. doi: 10.1016/j.jaci.2016.07.025.
［36］	Stepicheva NA, Song JL. Function and regulation of microRNA⁃31 in development and disease［J］. Mol Reprod Dev, 2016,83（8）:654⁃674. doi: 10.1002/mrd.22678.
［37］	Yan S, Xu Z, Lou F, et al. NF⁃κB⁃induced microRNA⁃31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis［J］. Nat Commun, 2015,6:7652. doi: 10.1038/ncomms8652.
［38］	Zhang W, Yi X, An Y, et al. MicroRNA⁃17⁃92 cluster promotes the proliferation and the chemokine production of keratinocytes: implication for the pathogenesis of psoriasis［J］. Cell Death Dis, 2018,9（5）:567. doi: 10.1038/s41419⁃018⁃0621⁃y.
［39］	Wu Y, Liu L, Bian C, et al. MicroRNA let⁃7b inhibits keratinocyte differentiation by targeting IL⁃6 mediated ERK signaling in psoriasis［J］. Cell Commun Signal, 2018,16（1）:58. doi: 10.1186/s12964⁃018⁃0271⁃9.
［40］	Yu X, An J, Hua Y, et al. MicroRNA⁃194 regulates keratinocyte proliferation and differentiation by targeting Grainyhead⁃like 2 in psoriasis［J］. Pathol Res Pract, 2017,213（2）:89⁃97. doi: 10. 1016/j.prp.2016.11.020.
［41］	Tang Y, Zhou T, Yu X, et al. The role of long non⁃coding RNAs in rheumatic diseases［J］. Nat Rev Rheumatol, 2017,13（11）:657⁃669. doi: 10.1038/nrrheum.2017.162.
［42］	Széll M, Danis J, Bata⁃Csörgő Z, et al. PRINS, a primate⁃specific long non⁃coding RNA, plays a role in the keratinocyte stress response and psoriasis pathogenesis［J］. Pflugers Arch, 2016,468（6）:935⁃943. doi: 10.1007/s00424⁃016⁃1803⁃z.
［43］	Danis J, Göblös A, Bata⁃Csörgő Z, et al. PRINS non⁃coding RNA regulates nucleic acid⁃induced innate immune responses of human keratinocytes［J］. Front Immunol, 2017,8:1053. doi: 10. 3389/fimmu.2017.01053.
［44］	Ahn R, Gupta R, Lai K, et al. Network analysis of psoriasis reveals biological pathways and roles for coding and long non⁃coding RNAs［J］. BMC Genomics, 2016,17（1）:841. doi: 10.1186/ s12864⁃016⁃3188⁃y.
［45］	Shao S, Gudjonsson JE. Epigenetics of psoriasis［J］. Adv Exp Med Biol, 2020,1253:209⁃221. doi: 10.1007/978⁃981⁃15⁃3449⁃2_8.
［46］	Qiao M, Ding J, Yan J, et al. Circular RNA expression profile and analysis of their potential function in psoriasis［J］. Cell Physiol Biochem, 2018,50（1）:15⁃27. doi: 10.1159/000493952.
［47］	Liu R, Wang Q, Chang W, et al. Characterisation of the circular RNA landscape in mesenchymal stem cells from psoriatic skin lesions［J］. Eur J Dermatol, 2019,29（1）:29⁃38. doi: 10.1684/ejd.2018.3483.
［48］	Batycka⁃Baran A, Hattinger E, Zwicker S, et al. Leukocyte⁃derived koebnerisin （S100A15） and psoriasin （S100A7） are systemic mediators of inflammation in psoriasis［J］. J Dermatol Sci, 2015,79（3）:214⁃221. doi: 10.1016/j.jdermsci.2015.05.007.
［49］	Glazewska EK, Niczyporuk M, Lawicki S, et al. ROC analysis of selected matrix metalloproteinases （MMPs） and tissue inhibitors of metalloproteinases （TIMPs） in psoriatic patients［J］. Postepy Dermatol Alergol, 2018,35（2）:167⁃173. doi: 10.5114/ada.2018.75238.
［50］	Qiao M, Li R, Zhao X, et al. Up⁃regulated lncRNA⁃MSX2P1 promotes the growth of IL⁃22⁃stimulated keratinocytes by inhibiting miR⁃6731⁃5p and activating S100A7［J］. Exp Cell Res, 2018,363（2）:243⁃254. doi: 10.1016/j.yexcr.2018.01.014.
［51］	Abhishek S, Palamadai Krishnan S. Epidermal differentiation complex: areview on its epigenetic regulation and potential drug targets［J］. Cell J, 2016,18（1）:1⁃6. doi: 10.22074/cellj.2016. 3980.
［52］	Guinea⁃Viniegra J, Jiménez M, Schonthaler HB, et al. Targeting miR⁃21 to treat psoriasis［J］. Sci Transl Med, 2014,6（225）:225re1. doi: 10.1126/scitranslmed.3008089.

[1]	肖春英王刚. 朗格汉斯细胞在银屑病中的作用研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 830-834.
[2]	周雪, 余增洋, 陈有东, 郭春源, 于倩, 胡艺凡, 姚玲玲, 史玉玲, . 肿瘤坏死因子α介导银屑病脂肪酸去饱和酶2低表达[J]. 中华皮肤科杂志, 2022, 55(9): 752-758.
[3]	姚玲玲, 余增洋郭春源周静崔莲于倩虞英媛周雪蔡江鲁伊史玉玲, . 节律基因隐花色素2在银屑病小鼠模型及HaCaT细胞中的表达变化及机制研究[J]. 中华皮肤科杂志, 2022, 55(9): 759-766.
[4]	俞晨王刚. [开放获取] 小分子靶向药物：银屑病治疗的新选择[J]. 中华皮肤科杂志, 2022, 55(9): 747-751.
[5]	郑佳媛余炳前陈显侠骆志成. 成人寻常型银屑病瘙痒特征及对生活质量的影响调查[J]. 中华皮肤科杂志, 2022, 55(9): 790-794.
[6]	孙杰王睿李承新. 肿瘤坏死因子α抑制剂诱导的银屑病研究进展[J]. 中华皮肤科杂志, 2022, 55(9): 821-824.
[7]	王玲艳潘靖苗钢常晓丹金秋子郭宁宁张佳钰. 对生物制剂治疗抵抗的银屑病患者皮损部位分析[J]. 中华皮肤科杂志, 2022, 55(7): 583-587.
[8]	中国医师协会皮肤科医师分会自身免疫病专业委员会 . 【开放获取】环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022, 55(6): 471-479.
[9]	闪莹左亚刚. 自身免疫性疱病与银屑病的相关性[J]. 中华皮肤科杂志, 2022, 55(5): 452-455.
[10]	王晓雯李若瑜. 白细胞介素17相关生物制剂治疗银屑病过程中浅部真菌感染的发生及应对策略[J]. 中华皮肤科杂志, 2022, 55(3): 272-275.
[11]	王召阳陈安薇向欣罗晓燕徐子刚王华马琳. 基于两家儿童医院信息系统的儿童银屑病现状调查[J]. 中华皮肤科杂志, 2022, 55(3): 246-250.
[12]	《脓疱型银屑病诊疗中国专家共识（版）》编写委员会专家组. 脓疱型银屑病诊疗中国专家共识（2022版）[J]. 中华皮肤科杂志, 2022, 55(3): 187-195.
[13]	王玥严煜林. 寻常型银屑病患者171例阿维A治疗相关不良反应及停药原因分析[J]. 中华皮肤科杂志, 2022, 55(3): 242-245.
[14]	李妍李明徐薇李邻峰. 【开放获取】丙酸氟替卡松乳膏单独或联合卡泊三醇软膏治疗轻中度斑块状银屑病的随机自身对照研究[J]. 中华皮肤科杂志, 2022, 55(3): 260-263.
[15]	张婷婷朱凤仪杨梅张平夏萍周小勇. 司库奇尤单抗治疗红皮病型银屑病7例的临床疗效及安全性观察[J]. 中华皮肤科杂志, 2022, 0(2): 20210644-e20210644.

银屑病表观遗传调控的研究进展

Epigenetic regulation in psoriasis

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 52

相关文章 15

Metrics

本文评价

推荐阅读 10